Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States.

Inoue K, Figueroa JF, DeJong CD, Tsugawa Y, Orav EJ, Shen C, Kazi DS. (2021). Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States.Circulation: Cardiovascular Quality and Outcomes: 14(5), e007521.